Mate to do investor conference they need something to talk about it. The device has been sitting on shelf for more then a year after getting CE approval is classic reason they can't afford to do investor conference as the first question will be "Why the FCKU you didn't make a single sell in a patient population four times more then what we have in New Zealand"?..IMO.
Ann: PanCO Clinical Study on OncoSil Published in ESMO Open, page-23
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |